Rznomics Announces FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma
SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
IRVINE, Calif., May 6, 2026 Helio Genomics announced publication of landmark clinical data demonstrating that its HelioLiverâ„¢ multi-analyte blood...
Woburn, Massachusetts | April 13, 2026 Sirtex Medical has announced groundbreaking results from its DOORwaY90 clinical study, demonstrating 100%...
Laval, Québec, December 1, 2025 — Morphocell Technologies has announced the successful completion of its US$50 million Series A...
Ramat Gan, Israel, November 26, 2025 — Can-Fite BioPharma has announced key updates across its advanced-stage clinical pipeline ahead...
